Department of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, The Netherlands. Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Academic Medical Center, Amsterdam, The Netherlands.
Am J Gastroenterol. 2018 Dec;113(12):1778-1787. doi: 10.1038/s41395-018-0212-7. Epub 2018 Aug 29.
Colorectal cancer (CRC) screening using fecal immunochemical tests (FIT) may reduce CRC-related mortality but its effectiveness is influenced by the limited accuracy of FIT. Identifying individuals at increased risk of a false FIT result could improve screening, but the available evidence is conflicting. We performed a systematic review and meta-analysis on risk factors for false-positive and false-negative FIT results in CRC screening.
A systematic search in MEDLINE, EMBASE, and Cochrane Library identified publications (before 29 January 2017) on risk factors (known at time of FIT invitation) associated with false FIT results (presence/absence of advanced neoplasia) in a CRC screening setting. Risk of bias was assessed using QUIPS. In meta-analysis, summary relative risk ratios and corresponding 95% confidence intervals were calculated for each risk factor.
Of 518 records identified, 14 studies with 54,499 participants in total were included for analysis. In meta-analysis, male sex was associated with a significantly lower risk of false-positivity (RR 0.84, CI 0.74-0.94), whereas participants using non-steroidal anti-inflammatory drugs (NSAIDs) had a higher risk (RR 1.16, CI 1.06-1.27). The use of anticoagulants was most frequently studied, without a significant effect on FIT positivity. Males (RR 1.83, CI 1.53-2.19), participants with a family history for CRC (RR 1.61, CI 1.19-2.15), hyperglycemia (RR 1.29, CI 1.02-1.65), hypertension (RR 1.50, CI 1.14-1.98), obesity (RR 1.38, CI 1.11-1.71), and (former) smokers (RR 1.93, CI 1.52-2.45) were all at significantly higher risk for false-negative results. Age was not found to have a systematic effect on either FIT false-positivity or false-negativity in meta-analysis.
Multiple risk factors, known at time of FIT invitation, are associated with false FIT results in CRC screening. This information can be used to identify populations risking false reassurance after a negative result or unnecessary colonoscopy after a positive result, and to further optimize CRC screening effectiveness.
粪便免疫化学检测(FIT)用于结直肠癌(CRC)筛查可能降低 CRC 相关死亡率,但该方法的有效性受到 FIT 检测准确性的限制。识别出 FIT 检测结果有误的高风险个体可能有助于改善筛查效果,但目前的证据相互矛盾。我们对 CRC 筛查中 FIT 检测结果阳性和阴性的假阳性和假阴性的相关危险因素进行了系统评价和荟萃分析。
通过 MEDLINE、EMBASE 和 Cochrane Library 系统检索了截至 2017 年 1 月 29 日的文献,纳入了结直肠癌筛查环境中与 FIT 检测结果(是否存在高级别肿瘤)相关的已知在 FIT 检测邀请时的危险因素(即已知风险因素)的相关研究。使用 QUIPS 工具评估偏倚风险。在荟萃分析中,计算了每个危险因素的综合相对风险比(RR)及其相应的 95%置信区间(CI)。
共纳入 518 篇文献,其中 14 项研究共纳入 54499 名参与者。荟萃分析结果显示,男性(RR 0.84,95%CI 0.74-0.94)的 FIT 假阳性风险显著降低,而使用非甾体类抗炎药(NSAIDs)(RR 1.16,95%CI 1.06-1.27)的风险升高。抗凝剂的使用最为常见,但对 FIT 检测的阳性结果无显著影响。男性(RR 1.83,95%CI 1.53-2.19)、CRC 家族史(RR 1.61,95%CI 1.19-2.15)、高血糖(RR 1.29,95%CI 1.02-1.65)、高血压(RR 1.50,95%CI 1.14-1.98)、肥胖(RR 1.38,95%CI 1.11-1.71)和(曾)吸烟者(RR 1.93,95%CI 1.52-2.45)的 FIT 假阴性风险显著增加。荟萃分析未发现年龄与 FIT 假阳性或假阴性结果之间存在系统关系。
CRC 筛查中,FIT 检测结果阳性或阴性的假阳性结果与多种已知在 FIT 检测邀请时的危险因素相关。这些信息可用于识别出在阴性结果后可能产生错误保证的人群,或在阳性结果后可能需要进行不必要的结肠镜检查的人群,从而进一步优化 CRC 筛查的效果。